Compass Therapeutics, Inc. — Director's Dealing 2021

Mar 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Compass Therapeutics, Inc. (CMPX)
CIK: 0001738021
Period of Report: 2021-02-09

Reporting Person: Schuetz Thomas J. (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-09	Stock Option (Right to Buy)	$5.00	A	700000	Acquired	2031-02-09	Common Stock (700000)	Direct

Footnotes

F1: 25% of this option vests on February 9, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.